Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Chronic kidney disease (CKD) is a continuously growing public health problem, affecting nowadays 8% to 16% of the general adult population around the world. As in other chronic pathologies, CKD was recently associated with an unbalanced gut microbiome. Several CKD-associated factors contribute to gut dysbiosis in CKD patients, such as uremic toxin accumulation, chronic inflammatory status, pharmacologic therapies, dietary restrictions, CKD-associated comorbidities, and the renal replacement therapies that end-stage kidney disease patients are subject to. However, this CKD-induced gut dysbiosis will further potentiate CKD progression due to several processes, namely, the production of uremic toxins of microbial-origin, intensification of renal and systemic inflammation, and, consequent increase in the cardiovascular risk. This chapter will describe up-to-date knowledge on the intrinsic relationship between gut microbiome and CKD and will cover future strategies toward prevention and treatment of intestinal dysbiosis that may ameliorate CKD progression.

More information Original publication

DOI

10.1016/B978-0-323-91313-3.00012-X

Type

Chapter

Publisher

Academic Press

Publication Date

2022-07-19T00:00:00+00:00

Keywords

Chronic kidney disease, Gut microbiome, Hemodialysis, Human microbiome, Kidney transplantation, Nutrition, Peritoneal dialysis, Renal disease, Renal replacement therapy, Uremic toxin